{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:56:05Z","timestamp":1793314565621,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Consorzio Interuniversitario Nazionale per la Bio-Oncologia"},{"name":"A.S.S.O. (Associazione Siciliana Sostegno Oncologico) Onlus"},{"name":"Borsa Dottorati FSE XXXII Ciclo Unime"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-3994-5","type":"journal-article","created":{"date-parts":[[2018,1,24]],"date-time":"2018-01-24T20:15:31Z","timestamp":1516824931000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review"],"prefix":"10.1186","volume":"18","author":[{"given":"Giuseppina Rosaria Rita","family":"Ricciardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tindara","family":"Franchina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Schifano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampiero","family":"Mastroeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Santacaterina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Adamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,25]]},"reference":[{"key":"3994_CR1","doi-asserted-by":"crossref","unstructured":"Loibl S, Gianni L. HER2-positive breast cancer. Lancet. 2017;389(10087):2415-2429.","DOI":"10.1016\/S0140-6736(16)32417-5"},{"issue":"3","key":"3994_CR2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ctrv.2012.05.006","volume":"39","author":"AI Mehta","year":"2013","unstructured":"Mehta AI, Brufsky AM, Sampson JH. Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier. Cancer Treat Rev. 2013;39(3):261\u20139.","journal-title":"Cancer Treat Rev"},{"issue":"23","key":"3994_CR3","doi-asserted-by":"publisher","first-page":"6404","DOI":"10.1158\/1078-0432.CCR-13-0790","volume":"19","author":"NU Lin","year":"2013","unstructured":"Lin NU, Amiri-Kordestani L, Palmieri D, Liewehr DJ, Steeg PS. CNS metastases in breast cancer: old challenge, new frontiers. Clin Cancer Res. 2013;19(23):6404\u201318.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3994_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.clbc.2016.07.002","volume":"17","author":"A Morikawa","year":"2017","unstructured":"Morikawa A, Jordan L, Rozner R, Patil S, Boire A, Pentsova E, et al. Characteristics and outcomes of patients with breast cancer with Leptomeningeal metastasis. Clin Breast Cancer. 2017;17(1):23\u20138.","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"3994_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11060-013-1092-8","volume":"113","author":"E Le Rhun","year":"2013","unstructured":"Le Rhun E, Taillibert S, Zairi F, Kotecki N, Devos P, Mailliez A, et al. A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer. J Neuro-Oncol. 2013;113(1):83\u201392.","journal-title":"J Neuro-Oncol"},{"issue":"6","key":"3994_CR6","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/S1470-2045(17)30312-1","volume":"18","author":"V Di\u00e9ras","year":"2017","unstructured":"Di\u00e9ras V, Miles D, Verma S, Pegram M, Welslau M, Baselga J, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(6):732\u201342.","journal-title":"Lancet Oncol."},{"issue":"6","key":"3994_CR7","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S1470-2045(17)30313-3","volume":"18","author":"IE Krop","year":"2017","unstructured":"Krop IE, Kim SB, Martin AG, LoRusso PM, Ferrero JM, Badovinac-Crnjevic T, et al. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017;18(6):743\u201354.","journal-title":"Lancet Oncol."},{"issue":"1","key":"3994_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/annonc\/mdu486","volume":"26","author":"IE Krop","year":"2015","unstructured":"Krop IE, Lin NU, Blackwell K, Guardino E, Huober J, Lu M, et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol. 2015;26(1):113\u20139.","journal-title":"Ann Oncol"},{"issue":"1","key":"3994_CR9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11060-013-1257-5","volume":"116","author":"R Bartsch","year":"2014","unstructured":"Bartsch R, Berghoff AS, Preusser M. Breast cancer brain metastases responding to primary systemic therapy with T-DM1. J Neuro-Oncol. 2014;116(1):205\u20136.","journal-title":"J Neuro-Oncol"},{"key":"3994_CR10","doi-asserted-by":"crossref","unstructured":"Torres S, Maralani P, Verma S. Activity of T-DM1 in HER-2 positive central nervous system breast cancer metastases. BMJ Case Rep. 2014;2014.","DOI":"10.1136\/bcr-2014-205680"},{"issue":"2","key":"3994_CR11","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1016\/j.clbc.2014.10.003","volume":"15","author":"R Kalsi","year":"2015","unstructured":"Kalsi R, Feigenberg S, Kwok Y, Tkaczuk K, Mehta M, Chumsri S. Brain metastasis and response to ado-trastuzumab emtansine: a case report and literature review. Clin Breast Cancer. 2015;15(2):e163\u20136.","journal-title":"Clin Breast Cancer"},{"key":"3994_CR12","doi-asserted-by":"crossref","unstructured":"Keith KC, Lee Y, Ewend MG, Zagar TM, Anders CK. Activity of Trastuzumab Emtansine (TDM1) in HER2-positive breast cancer brain metastases: a case series. Cancer Treat Commun. 2016;7:43\u20136.","DOI":"10.1016\/j.ctrc.2016.03.005"},{"issue":"7","key":"3994_CR13","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s10585-015-9740-3","volume":"32","author":"R Bartsch","year":"2015","unstructured":"Bartsch R, Berghoff AS, Vogl U, Rudas M, Bergen E, Dubsky P, et al. Activity of T-DM1 in Her2-positive breast cancer brain metastases. Clin Exp Metastasis. 2015;32(7):729\u201337.","journal-title":"Clin Exp Metastasis"},{"issue":"2","key":"3994_CR14","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s10549-016-3828-6","volume":"157","author":"W Jacot","year":"2016","unstructured":"Jacot W, Pons E, Frenel JS, Guiu S, Levy C, Heudel PE, et al. Efficacy and safety of trastuzumabemtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases. Breast Cancer Res Treat. 2016;157(2):307\u201318.","journal-title":"Breast Cancer Res Treat"},{"key":"3994_CR15","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.14694\/EDBK_100006","volume":"35","author":"VA Venur","year":"2016","unstructured":"Venur VA, Ahluwalia MS. Targeted therapy in brain metastases: ready for primetime? Am Soc Clin Oncol Educ Book. 2016;35:e123\u201330.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"3994_CR16","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ctrv.2016.03.014","volume":"46","author":"C Fontanella","year":"2016","unstructured":"Fontanella C, De Carlo E, Cinausero M, Pelizzari G, Venuti I, Puglisi F. Central nervous system involvement in breast cancer patients: is the therapeutic landscape changing too slowly? Cancer Treat Rev. 2016;46:80\u20138.","journal-title":"Cancer Treat Rev"},{"key":"3994_CR17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.breast.2016.10.006","volume":"31","author":"C Phillips","year":"2017","unstructured":"Phillips C, Jeffree R, Khasraw M. Management of breast cancer brain metastases: a practical review. Breast. 2017;31:90\u20138.","journal-title":"Breast"},{"issue":"1","key":"3994_CR18","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1093\/neuonc\/now197","volume":"19","author":"MC Chamberlain","year":"2017","unstructured":"Chamberlain MC, Baik CS, Gadi VK, Bhatia S, Chow LQ. Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma. Neuro-Oncology. 2017;19(1):i1\u2013i24.","journal-title":"Neuro-Oncology"},{"issue":"1","key":"3994_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00109-013-1108-z","volume":"92","author":"DH Murrell","year":"2014","unstructured":"Murrell DH, Foster PJ, Chambers AF. Brain metastases from breast cancer: lessons from experimental magnetic resonance imaging studies and clinical implications. J Mol Med (Berl). 2014;92(1):5\u201312.","journal-title":"J Mol Med (Berl)"},{"issue":"4","key":"3994_CR20","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s10585-016-9784-z","volume":"33","author":"CE Adkins","year":"2016","unstructured":"Adkins CE, Mohammad AS, Terrell-Hall TB, Dolan EL, Shah N, Sechrest E, et al. Characterization of passive permeability at the blood-tumor barrier in five preclinical models of brain metastases of breast cancer. Clin Exp Metastasis. 2016;33(4):373\u201383.","journal-title":"Clin Exp Metastasis"},{"issue":"23","key":"3994_CR21","doi-asserted-by":"publisher","first-page":"5664","DOI":"10.1158\/1078-0432.CCR-10-1564","volume":"16","author":"PR Lockman","year":"2010","unstructured":"Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res. 2010;16(23):5664\u201378.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3994_CR22","first-page":"683","volume":"9","author":"M vanVulpen","year":"2002","unstructured":"vanVulpen M, Kal HB, Taphoorn MJ, El-Sharouni SY. Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (review). Oncol Rep. 2002;9(4):683\u20138.","journal-title":"Oncol Rep"},{"issue":"1","key":"3994_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/01.cad.0000236313.50833.ee","volume":"18","author":"HJ Stemmler","year":"2007","unstructured":"Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anti-Cancer Drugs. 2007;18(1):23\u20138.","journal-title":"Anti-Cancer Drugs"},{"issue":"5","key":"3994_CR24","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/clpt.2010.12","volume":"87","author":"EC Dijkers","year":"2010","unstructured":"Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87(5):586\u201392.","journal-title":"Clin Pharmacol Ther"},{"key":"3994_CR25","first-page":"289","volume":"8","author":"GR Ricciardi","year":"2015","unstructured":"Ricciardi GR, Russo A, Franchina T, Ferraro G, Adamo V. Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases. Onco Targets Ther. 2015;8:289\u201394.","journal-title":"Onco Targets Ther"},{"issue":"6","key":"3994_CR26","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1093\/annonc\/mdt036","volume":"24","author":"EM Olson","year":"2013","unstructured":"Olson EM, Abdel-Rasoul M, Maly J, Wu CS, Lin NU, Shapiro CL. Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab. Ann Oncol. 2013;24(6):1526\u201333.","journal-title":"Ann Oncol"},{"issue":"3","key":"3994_CR27","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s11060-007-9420-5","volume":"85","author":"R Bartsch","year":"2007","unstructured":"Bartsch R, Rottenfusser A, Wenzel C, Dieckmann K, Pluschnig U, Altorjai G, et al. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J Neuro-Oncol. 2007;85(3):311\u20137.","journal-title":"J Neuro-Oncol"},{"issue":"3","key":"3994_CR28","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s11060-016-2075-3","volume":"127","author":"R Rostami","year":"2016","unstructured":"Rostami R, Mittal S, Rostami P, Tavassoli F, Jabbari B. Brain metastasis in breast cancer: a comprehensive literature review. J Neuro-Oncol. 2016;127(3):407\u201314.","journal-title":"J Neuro-Oncol"},{"issue":"5","key":"3994_CR29","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1634\/theoncologist.2014-0107","volume":"20","author":"Q Shen","year":"2015","unstructured":"Shen Q, Sahin AA, Hess KR, Suki D, Aldape KD, Sawaya R, et al. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis. Oncologist. 2015;20(5):466\u201373.","journal-title":"Oncologist"},{"issue":"3","key":"3994_CR30","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ijrobp.2010.06.057","volume":"81","author":"C Chargari","year":"2011","unstructured":"Chargari C, Idrissi HR, Pierga JY, Bollet MA, Di\u00e9ras V, Campana F, et al. Preliminary results of whole brain radiotherapy with concurrent trastuzumab for treatment of brain metastases in breast cancer patients. Int J Radiat Oncol Biol Phys. 2011;81(3):631\u20136.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"3994_CR31","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1200\/JCO.2007.12.3588","volume":"26","author":"NU Lin","year":"2008","unstructured":"Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008;26(12):1993\u20139.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3994_CR32","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1158\/1078-0432.CCR-08-1080","volume":"15","author":"NU Lin","year":"2009","unstructured":"Lin NU, Di\u00e9ras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009;15(4):1452\u20139.","journal-title":"Clin Cancer Res"},{"issue":"15S Supplement","key":"3994_CR33","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1200\/jco.2008.26.15_suppl.1094","volume":"26","author":"F Boccardo","year":"2008","unstructured":"Boccardo F, Kaufman B, Baselga J, Dieras V, Link J, Casey MA, et al. Evaluation of lapatinib plus capecitabinein patients with brain metastases from HER2+ breast cancer enrolled in the Lapatinib expanded access program (LEAP) and French AuthorisationTemporaired\u2019Utilisation (ATU). J Clin Oncol. 2008;26(15S Supplement):1094.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3994_CR34","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/annonc\/mdq434","volume":"22","author":"G Metro","year":"2011","unstructured":"Metro G, Foglietta J, Russillo M, Stocchi L, Vidiri A, Giannarelli D, et al. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol. 2011;22(3):625\u201330.","journal-title":"Ann Oncol"},{"issue":"6","key":"3994_CR35","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/sj.bjc.6605586","volume":"102","author":"S Sutherland","year":"2010","unstructured":"Sutherland S, Ashley S, Miles D, Chan S, Wardley A, Davidson N, et al. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience. Br J Cancer. 2010;102(6):995\u20131002.","journal-title":"Br J Cancer"},{"issue":"1","key":"3994_CR36","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S1470-2045(12)70432-1","volume":"14","author":"T Bachelot","year":"2013","unstructured":"Bachelot T, Romieu G, Campone M, Di\u00e9ras V, Cropet C, Dalenc F, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14(1):64\u201371.","journal-title":"Lancet Oncol"},{"issue":"3","key":"3994_CR37","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s11060-011-0629-y","volume":"105","author":"NU Lin","year":"2011","unstructured":"Lin NU, Eierman W, Greil R, Campone M, Kaufman B, Steplewski K, et al. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neuro-Oncol. 2011;105(3):613\u201320.","journal-title":"J Neuro-Oncol"},{"issue":"14","key":"3994_CR38","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1200\/JCO.2014.57.1794","volume":"33","author":"X Pivot","year":"2015","unstructured":"Pivot X, Manikhas A, \u017burawski B, Chmielowska E, Karaszewska B, Allerton R, et al. CEREBEL (EGF111438): a phase III, randomized, open-label study of Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2015;33(14):1564\u201373.","journal-title":"J Clin Oncol"},{"issue":"6","key":"3994_CR39","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1093\/annonc\/mdu133","volume":"25","author":"SM Swain","year":"2014","unstructured":"Swain SM, Baselga J, Miles D, Im YH, Quah C, Lee LF, et al. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann Oncol. 2014;25(6):1116\u201321.","journal-title":"Ann Oncol"},{"key":"3994_CR40","doi-asserted-by":"publisher","unstructured":"Askoxylakis V, Ferraro GB, Kodack DP, Badeaux M, Shankaraiah RC, Seano G, et al. Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment. J Natl Cancer Inst. 2015;108(2). doi: https:\/\/doi.org\/10.1093\/jnci\/djv313 . Print 2016 Feb.","DOI":"10.1093\/jnci\/djv313"},{"issue":"2","key":"3994_CR41","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/neuonc\/nou141","volume":"17","author":"A Morikawa","year":"2015","unstructured":"Morikawa A, Peereboom DM, Thorsheim HR, Samala R, Balyan R, Murphy CG, et al. Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. Neuro-Oncology. 2015;17(2):289\u201395.","journal-title":"Neuro-Oncology"},{"issue":"2","key":"3994_CR42","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s11060-015-2045-1","volume":"127","author":"CL de Vries","year":"2016","unstructured":"de Vries CL, Linn SC, Brandsma D. Response of symptomatic brain metastases from HER-2 overexpressing breast cancer with T-DM1. J Neuro-Oncol. 2016;127(2):401\u20133.","journal-title":"J Neuro-Oncol"},{"key":"3994_CR43","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1186\/s12885-016-2464-1","volume":"16","author":"K Mitsuya","year":"2016","unstructured":"Mitsuya K, Watanabe J, Nakasu Y, Hayashi N, Harada H, Ito I. Expansive hematoma in delayed cerebral radiation necrosis in patients treated with T-DM1: a report of two cases. BMC Cancer. 2016;16:391.","journal-title":"BMC Cancer"},{"issue":"7","key":"3994_CR44","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1093\/neuonc\/not329","volume":"16","author":"JA Carlson","year":"2014","unstructured":"Carlson JA, Nooruddin Z, Rusthoven C, Elias A, Borges VF, Diamond JR, et al. Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema. Neuro-Oncology. 2014;16(7):1006\u20139.","journal-title":"Neuro-Oncology"},{"key":"3994_CR45","first-page":"586","volume":"9","author":"GS Borges","year":"2015","unstructured":"Borges GS, Rovere RK, Dias SM, Chong FH, Morais MS. Safety and efficacy of the combination of T-DM1 with radiotherapy of the central nervous system in a patient with HER2-positive metastatic breast cancer: case study and review of the literature. E Cancer Med Sci. 2015;9:586.","journal-title":"E Cancer Med Sci"},{"issue":"1","key":"3994_CR46","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11060-016-2265-z","volume":"131","author":"A Geraud","year":"2017","unstructured":"Geraud A, Xu HP, Beuzeboc P, Kirova YM. Preliminary experience of the concurrent use of radiosurgery and T-DM1 for brain metastases in HER2-positive metastatic breast cancer. J Neuro-Oncol. 2017;131(1):69\u201372.","journal-title":"J Neuro-Oncol"},{"key":"3994_CR47","unstructured":"Zagar TM, Van Swearingen AE, Kaidar-Person O, Ewend MG, Anders CK. Multidisciplinary Management of Breast Cancer Brain Metastases. Oncology (Williston Park). 2016;30(10):923-33."},{"key":"3994_CR48","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jocn.2015.11.012","volume":"27","author":"JV Brower","year":"2016","unstructured":"Brower JV, Saha S, Rosenberg SA, Hullett CR, Ian RH. Management of leptomeningeal metastases: prognostic factors and associated outcomes. J Clin Neurosci. 2016;27:130\u20137.","journal-title":"J Clin Neurosci"},{"key":"3994_CR49","doi-asserted-by":"crossref","unstructured":"Borges VF, Ferrario C, Aucoin N, Falkson CI, Khan QJ, Krop IE, et al. Efficacy results of a phase 1b study of ont-380, a CNS-penetrant TKI, in combination with T-DM1 in HER2+ metastatic breast cancer (MBC), including patients (pts) with brain metastases. J Clin Oncol 34, 2016 (suppl; abstr 513).","DOI":"10.1200\/JCO.2016.34.15_suppl.513"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-3994-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T15:50:27Z","timestamp":1570636227000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-3994-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,25]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3994"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-3994-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,25]]},"assertion":[{"value":"23 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"97"}}